Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rosa Yelmo is active.

Publication


Featured researches published by Rosa Yelmo.


Diabetes Research and Clinical Practice | 2016

Impact of insulin pump therapy on long-term glycemic control in a pediatric Spanish cohort

Esmeralda Colino; M. Martín-Frías; Rosa Yelmo; M Ángeles Álvarez; Belén Roldán; Raquel Barrio

AIMS To evaluate the efficacy and safety of Continuous Subcutaneous Insulin Infusion (CSII) in a pediatric cohort and to determine if the ISPAD/IDF/ADA criteria for good metabolic control are achieved during long periods of time. METHODS Retrospective longitudinal study including ninety patients [10.5 (6.5-13.9) years of age, 58% males]. Age at debut, type 1 diabetes mellitus duration, pubertal stage, HbA1c, insulin dose, mean number of glycemic controls, number of basal rates, % basal/total insulin, severe hypoglycemia and diabetic ketoacidosis events were analyzed. Subgroup analysis based on age and pubertal stage was performed. RESULTS HbA1c decreased from 6.9% [52 mmol/mol] to 6.7% [50 mmol/mol] after one year of CSII. Afterwards, it remained less than 7% during the follow-up period (median 3.5 ± 1.8 years (range 1-8). Prior to CSII, 76% of the subjects met ISPAD/ADA criteria. One year after initiating CSII, 96% of children had HbA1c<7.5%. Improvement in glycohemoglobin levels was most prominent in those patients with the highest HbA1c initial levels. Total insulin dose decreased from 0.89 to 0.73 UI/kg/day (p<0.001). Proportion of basal/total insulin changed significantly (47 to 42% (p<0.05)). Number of fractions of the basal rate increased from 5.6 ± 1.8 at one year of CSII to 6.7 ± 2.1 five years later. Incidence of severe hypoglycemic events decreased from 19 to 6.9 episodes/100 patient-year. Only 2 episodes of diabetic ketoacidosis occurred. CONCLUSIONS CSII allows reaching ISPAD/IDF/ADA goals safely during an extended follow-up period in a diabetic pediatric cohort.


Anales De Pediatria | 2017

Infusión subcutánea continua de insulina en menores de 6 años: evolución a largo plazo

Esmeralda Colino; María Martín Frías; Belén Roldán; María Ángeles Álvarez; Rosa Yelmo; Raquel Barrio

OBJECTIVE The aims of the study are to evaluate the efficacy and safety of continuous subcutaneous insulin infusion (CSII) treatment in pre-school children with type I diabetes, and to assess whether the criteria of good metabolic control are achieved. METHOD A review was performed on the medical charts of patients<6 years of age who started CSII treatment between 2003 and 2014. The cohort consisted of 27 patients (mean age 4 (2.9-4.7) years, 56% males). An analysis was made including the age at onset, type I diabetes duration, HbA1c (HPLC, Menarini, normal value 5.1±0.31%), insulin dose (u/kg/day), number of capillary blood glucose measurements, number of baseline processes per day, % baseline/total insulin (B/TI), insulin ratios (I/HC) at different meals, severe hypoglycaemia (HS episodes/100 patients years), DKA events, percentages of normal blood glucose (70-180mg/dl), hyperglycaemia (>180mg/dl), and hypoglycaemia (<70mg/dl), mean blood glucose, standard deviation and coefficient of variation (SD/mean glucose ×100). Statistical analysis was performed using SPSS. RESULTS HbA1c decreased from 6.9% (6.7-7.5) to 6.8% (6.4-7.1) after one year of CSII. Afterwards, it remained under 6.8% during the follow-up (median 5 years [3-6]). Prior to CSII, 74% of children had HbA1c levels < 7.5%. It increased to 96% after one year of CSII. Median blood glucose measurements /day was 10 (9-11). Total insulin dose did not change significantly. During the follow-up, there was one episode of DKA and one episode of HS. I/HC at breakfast were higher than at other meals (0.92 vs. 0.55, 0.6 and 0.5, respectively). CONCLUSIONS CSII is effective and safe in pre-school children. It allows good metabolic control (based on Society for Paediatric and Adolescent Diabetes / American Diabetes Association criteria) to be achieved and maintained for long periods of time without an increase in adverse events.


Anales De Pediatria | 2017

La respuesta monofásica a la sobrecarga oral de glucosa como factor predictivo del riesgo de diabetes tipo 2 en pacientes pediátricos con obesidad

Aura D. Herrera-Martínez; Patricia Enes; M. Martín-Frías; Belén Roldán; Rosa Yelmo; Raquel Barrio

INTRODUCTION The onset of obesity at young ages is strongly associated with the early development of type 2diabetes (T2D). The shape of the curves of glucose and insulin curves during an oral glucose tolerance test (OGTT) could predict the risk of developing T2D. OBJECTIVE To analyse the morphology of the OGTT and determine T2D risk factors in a mainly Caucasian population of children and adolescents. METHODS Observational retrospective study including 588 patients (309 males, 279 females) with a mean age of 11.1±2years, and of whom 90.3% were Caucasian. Risk factors for T2D were compared in patients with a monophasic or biphasic pattern during the performance of an OGTT, as well as anthropometric and biochemical variables, insulin resistance, and beta-cell function. RESULTS The shape of the glucose curve was monophasic in 50.2% of patients (50.8% male), biphasic in 48.5% (47.6% males), and indeterminate in 1.3%. The monophasic pattern showed lower insulin-sensitivity and worse beta-cell function. Patients with a biphasic pattern had a higher BMI, waist circumference, and blood pressure, although the results were not significant. Latin-American patients had significantly lower serum glucose levels with higher insulin levels during the OGTT. CONCLUSIONS The pattern of response to an OGTT reflects different metabolic phenotypes. Paediatric patients with a biphasic pattern have lower risk-profiling for T2D. The performing of an OGTT could be useful to implement early intervention strategies in children and adolescents with obesity, in order to prevent the development of pre-diabetes or T2D.


Diabetes Research and Clinical Practice | 2015

Achievement of metabolic control goals set by the American Diabetes Association and the International Society for Pediatric and Adolescent Diabetes in pediatric patients with type 1 diabetes from Spain

Patricia Enes; M. Martín-Frías; Mª Ángeles Álvarez; Rosa Yelmo; Milagros Alonso; Raquel Barrio


Anales De Pediatria | 2017

Continuous subcutaneous insulin infusion in children less than 6 years-old: Long-term progress

Esmeralda Colino; María Martín Frías; Belén Roldán; María Ángeles Álvarez; Rosa Yelmo; Raquel Barrio


Anales De Pediatria | 2017

The monophasic pattern in oral glucose tolerance test as a predictive risk factor of type 2 diabetes in obese paediatric patients

Aura D. Herrera-Martínez; Patricia Enes; M. Martín-Frías; Belén Roldán; Rosa Yelmo; Raquel Barrio


55th Annual ESPE | 2016

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion Treatment in Pre-schoolers. Long Term Experience of a Tertiary Care Centre in Spain

Esmeralda Colino; Beatriz Villafuerte; Maria Martin; Belén Roldán; Angeles Alvarez; Rosa Yelmo; Raquel Barrio


55th Annual ESPE | 2016

Analysis of Short-Term Efficacy of MiniMed 640G with SmartGuard in Pediatric Patients with Type 1 Diabetes

Beatriz Villafuerte; M. Martín-Frías; Rosa Yelmo; Belén Roldán; Alvarez M. Angeles; Raquel Barrio


Archive | 2015

Influence of Pancreatic Autoinmunity in the Onset and Progression of Diabetes in Paediatric Population

Yoko Oyakawa; M. Martín-Frías; Rosa Yelmo; Milagros Alonso; Belén Roldán; Raquel Barrio


ESPE 2014 | 2014

Efficacy and Safety of CSII Treatment in Paediatric Age: Long Term Experience of a Tertiary Care Centre in Spain

Belén Roldán; Esmeralda Colino; M. Martín-Frías; Angeles Alvarez; Rosa Yelmo; Raquel Barrio

Collaboration


Dive into the Rosa Yelmo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge